Renal endothelin in FK5O6-induced nephrotoxicity in spontaneously hypertensive rats

Japanese Journal of Pharmacology

Volumn 76, Issue 1, 1998, Pages 39-49

  Uchida, Junji ^a   Miura, Katsuyuki ^a   Yamanaka, Shinya ^a   Kim, Shokei ^a   Iwao, Hiroshi ^a   Nakatani, Tatsuya ^a   Kishimoto, Taketoshi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Endothelin; FK506; Nephrotoxicity; Spontaneously hypertensive rats; TAK 044

Indexed keywords

ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; MESSENGER RNA; TACROLIMUS; TAK 044; CYCLOPEPTIDE; ENDOTHELIN A RECEPTOR; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MALE; NEPHROTOXICITY; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASOCONSTRICTION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY DISEASE; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASCULARIZATION;

ANIMALS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; GLOMERULAR FILTRATION RATE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; MALE; PEPTIDES, CYCLIC; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; RNA, MESSENGER; TACROLIMUS; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 0031594240     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.76.39     Document Type: Article

References (57)

1. Schreiber SL and Crabtree GR: The mechanism of action of cyclosporin A and FK506. Review. Immunol Today 13, 136-142 (1992)
2. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ and O'Neill EA: FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 357, 692-694 (1992)
3. Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett J Jr, Gores G, Hay E, Dickson ER and Krom RA: Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 55, 1332-1339 (1993)
4. Lanese DM and Conger JD: Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 91, 2144-2149 (1993)
5. Lanese DM, Falk SA and Conger JD: Sequential agonist activation and site-specific mediation of acute cyclosporine constriction in rat renal arterioles. Transplantation 58, 1371-1378 (1994)
6. Perico N, Dadan J and Remuzzi G: Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1, 76-83 (1990)
7. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I and Hoover RL: Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 37, 1487-1491 (1990)
8. Fogo A, Hellings SE, Inagami T and Kon V: Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int 42, 770-774 (1992)
9. Kivlighn SD, Gabel RA and Siegl PK: Effects of BQ-123 on renal function and acute cyclosporine-induced renal dysfunction. Kidney Int 45, 131-136 (1994)
10. Conger JD, Kim GE and Robinette JB: Effects of ANG II, ETA and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction. Am J Physiol 267, F443-F449 (1994)
11. Davis LS, Haleen SJ, Doherty AM, Cody WL and Keiser JA: Effects of selective endothelin antagonists on the hemodynamic response to cyclosporin A. J Am Soc Nephrol 4, 1448-1454 (1994)
12. Hunley TE, Fogo A, Iwasaki S and Kon V: Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 5, 1718-1723 (1995)
13. Kon V, Hunley TE and Fogo A: Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Studies in chronic cyclosporine nephrotoxicity in rats. Transplantation 60, 89-95 (1995)
14. Tanda K, Seki T, Kobayashi S, Kanagawa K, Chikaraishi T, Togashi M, Nonomura K and Koyanagi T: In vivo effect of a selective endothelin receptor antagonist, BQ-123, on renal function in cyclosporin A-treated rats. Int J Urol 1, 309-315 (1994)
15. Abassi ZA, Pieruzzi F, Nakhoul F and Keiser HR: Effects of cyclosporin A on the synthesis, excretion, and metabolism of endothelin in the rat. Hypertension 27, 1140-1148 (1996)
16. Bartholomeusz B, Hardy KJ, Nelson AS and Phillips PA: Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates. Hypertension 27, 1341-1345 (1996)
17. Takeda Y, Miyamori I, Wu P, Yoneda T, Furukawa K and Takeda R: Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 26, 932-936 (1995)
18. Leszczynski D, Zhao Y, Yeagley TJ and Foegh ML: Direct and endothelial cell-mediated effect of cyclosporin A on the proliferation of rat smooth muscle cells in vitro. Am J Pathol 142, 149-155 (1993)
19. Bunchman TE and Brookshire CA: Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 88, 310-314 (1991)
20. Copeland KR and Yatscoff RW: Comparison of the effects of cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells. Transplantation 53, 640-645 (1992)
21. Moutabarrik A, Ishibashi M, Fukunaga M, Kameoka H, Kawaguchi N, Takano Y, Kokado Y, Sonoda T, Onishi S, Takahara S and Okuyama A: FK506-induced kidney tubular cell injury. Transplantation 54, 1041-1047 (1992)
22. Goodall T, Kind CN and Hammond TG: FK506-induced endothelin release by cultured rat mesangial cells. J Cardiovasc Pharmacol 26, S482-S485 (1995)
23. Takeda Y, Yoneda T, Ito Y, Miyamori I and Takeda R: Stimulation of endothelin mRNA and secretion in human endothelial cells by FK 506. J Cardiovasc Pharmacol 22, S310-S312 (1993)
24. Nakahama H, Fukunaga M, Kakihara M, Horio M, Fujiwara Y, Fukuhara Y, Ueda N, Orita Y and Kamada T: Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. J Cardiovasc Pharmacol 17, S172-S173 (1991)
25. Benigni A, Morigi M, Perico N, Zoja C, Amuchastegui CS, Piccinelli A, Donadelli R and Remuzzi G: The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation 54, 775-780 (1992)
26. Hammond TG and Kind CN: Pancreatic and nephrotoxicity of immunomodulator compounds. Review. Toxicol Lett 83, 99-105 (1995)
27. Mitamura T, Yamada A, Ishida H, Fujihira S, Ohara K, Noguchi H and Mine Y: Tacrolimus (FK506)-induced nephrotoxicity in spontaneous hypertensive rats. J Toxicol Sci 19, 219-226 (1994)
28. Ikeda S, Awane Y, Kusumoto K, Wakimasu M, Watanabe T and Fujino M: A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ETA- and ETB-mediated blood pressure responses in rats. J Pharmacol Exp Ther 270, 728-733 (1994)
29. Perico N, Amuchastegui CS, Zoja C, Benigni A, Morigi M and Remuzzi G: FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. Transplant Proc 23, 3123-3125 (1991)
30. B-receptor agonist, in anesthetized rats. Jpn J Pharmacol 71, 213-222 (1996)
31. Walser M, Davidson DG and Orloff J: The renal clearance of alkali-stable inulin. J Clin Invest 34, 1520-1523 (1955)
32. Sakurai T, Yanagisawa M, Inoue A, Ryan US, Kimura S, Mitsui Y, Goto K and Masaki T: cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem Biophys Res Commun 175, 44-47 (1991)
33. Hori S, Komatsu Y, Shigemoto R, Mizuno N and Nakanishi S: Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. Endocrinology 130, 1885-1895 (1992)
34. Fort P, Marty L, Piechaczyk M, el Sabrouty S, Dani C, Jeanteur P and Blanchard JM: Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 13, 1431-1442 (1985)
35. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F and Iwao H: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24, 195-204 (1994)
36. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, Christians U, Winkler M, Fitzsimmons WE, Lieberman R, McBride J, Kobayashi M, Warty V and Soldin JS: Consensus document: therapeutic monitoring of tacrolimus (FK-506). Review. Ther Drug Monit 17, 606-614 (1995)
37. Fujita K, Matsumura Y, Kita S, Hisaki K, Takaoka M and Morimoto S: Phosphoramidon-sensitive conversion of big endothelin-1 and degradation of endothelin-1 in rat kidney. Hypertension 24, 227-233 (1994)
38. Miura K, Yukimura T, Yamashita Y, Shichino K, Shimmen T, Saito M, Okumura M, Imanishi M, Yamanaka S and Yamamoto K: Effects of endothelin on renal hemodynamics and renal function in anesthetized dogs. Am J Hypertens 3, 632-634 (1990)
39. Miura K, Yukimura T, Yamashita Y, Shimmen T, Okumura M, Yamanaka S, Imanishi M and Yamamoto K: Renal and femoral vascular responses to endothelin-1 in dogs: role of prostaglandins. J Pharmacol Exp Ther 256, 11-17 (1991)
40. Yamashita Y, Yukimura T, Miura K, Okumura M and Yamamoto K: Effects of endothelin-3 on renal functions. J Pharmacol Exp Ther 259, 1256-1260 (1991)
41. Yukimura T, Yamashita Y, Miura K, Kim S, Iwao H, Takai M and Okada T: Renal vasodilating and diuretic actions of a selective endothelin ETB receptor agonist, IRL1620. Eur J Pharmacol 264, 399-405 (1994)
42. Clozel M, Gray GA, Breu V, Loffler BM and Osterwalder R: The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 186, 867-873 (1992)
43. Kato T, Kassab S, Wilkins F Jr, Kirchner KA, Keiser J and Granger JP: Endothelin antagonists improve renal function in spontaneously hypertensive rats. Hypertension 25, 883-887 (1995)
44. Li JS and Schiffrin EL: Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 25, 495-500 (1995)
45. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M, Ishikawa K and Ikemoto F: Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci 52, 717-724 (1993)
46. Douglas SA, Gellai M, Ezekiel M, Feuerstein GZ, Elliott JD and Ohlstein EH: Antihypertensive actions of the novel non-peptide endothelin receptor antagonist SB 209670. Hypertension 25, 818-822 (1995)
47. Mehring N, Neumann KH, Rahn KH and Zidek W: Mechanisms of ciclosporin A-induced vasoconstriction in the isolated perfused rat kidney. Nephron 60, 477-481 (1992)
48. Perico N, Rossini M, Imberti O, Malanchini B, Cornejo RP, Gaspari F, Bertani T and Remuzzi G: Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft. J Am Soc Nephrol 2, 1398-1404 (1992)
49. Rossini M, Belloni A, Remuzzi G and Perico N: Thromboxane receptor blockade attenuates the toxic effect of cyclosporine in experimental renal transplantation. Circulation 81, Suppl 1, 161-167 (1990)
50. Mervaala EM, Pere AK, Lindgren L, Laakso J, Teravainen TL, Karjala K, Vapaatalo H, Ahonen J and Karppanen H: Effects of dietary sodium and magnesium on cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension 29, 822-827 (1997)
51. Iwasaki S, Homma T and Ron V: Site specific regulation in the kidney of endothelin and its receptor subtypes by cyclosporine. Kidney Int 45, 592-597 (1994)
52. Muraoka K, Fujimoto K, Sun X, Yoshioka K, Shimizu K, Yagi M, Bose H Jr, Miyazaki I and Yamamoto K: Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. J Clin Invest 97, 2433-2439 (1996)
53. Iwai J, Kanayama Y, Negoro N, Okamura M and Takeda T: Gene expression of endothelin receptors in aortic cells from cyclosporine-induced hypertensive rats. Clin Exp Pharmacol Physiol 22, 404-409 (1995)
54. Su Q, Weber L, Le Hir M, Zenke G and Ryffel B: Nephrotoxicity of cyclosporin A and FK 506: inhibition of calcineurin phosphatase. Ren Physiol Biochem 18, 128-139 (1995)
55. Nielsen FT, Leyssac PP, Kemp E, Starklint H and Dieperink H: Nephrotoxicity of FK-506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity. Nephrol Dial Transplant 10, 334-340 (1995)
56. Ryffel B, Weber E and Mihatsch MJ: Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin. Exp Nephrol 2, 324-333 (1994)
57. Muhl H, Kunz D, Rob P and Pfeilschifter J: Cyclosporin derivatives inhibit interleukin 1 beta induction of nitric oxide synthase in renal mesangial cells. Eur J Pharmacol 249, 95-100 (1993)